The most commonly reported undesirable effect was nausea. (See Table 3.)
Click on icon to see table/diagram/image
Bleeding patterns may be temporarily disturbed, but most women will have their next menstrual period within 5-7 days of the expected time.
If the next menstrual period is more than 5 days overdue pregnancy should be excluded.
From Post-marketing surveillance additionally, the following adverse events have been reported: Skin and subcutaneous tissue disorders: Very rare (<1/10,000): rash, urticaria, pruritus.
Reproductive system and breast disorders: Very rare (<1/10,000): pelvic pain, dysmenorrhoea.
Gastrointestinal disorders: Very rare (<1/10,000): abdominal pain.
General disorders and administration site conditions: Very rare (<1/10,000): face oedema.
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.